When was Systimmune founded?

Systimmune was founded in 2014.

Where is Systimmune located?

Systimmune is headquartered in Redmond, United States. It is registered at Redmond, Washington.

How many employees does Systimmune have?

As of Jul 31, 2026, the latest employee count at Systimmune is 145.

Where does Systimmune rank among its competitors?

Systimmune ranks 1100th amongst 3337 active competitors, of which 1140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Systimmune?

Systimmune's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Systimmune - 2026 Company Profile & Competitors

Company Details

Biopharmaceutical company developing innovative antibody-based therapies for cancer treatment. Focused on creating biologics that directly attack tumors and activate the immune system, the company develops bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Leveraging advanced technology platforms and a multidisciplinary team of R&D scientists, clinical experts, and biotech business professionals, the company aims to deliver transformative treatments to patients worldwide. The company's capabilities include protein engineering, antibody development, and process development, utilizing CHO production platforms to manufacture biotherapeutics. With active discovery efforts and clinical development operations, the company is committed to advancing an ambitious R&D pipeline and delivering the next generation of breakthrough cancer therapies.

Website: systimmune.com
Social
Email ID: *****@systimmune.com
Phone Number: +1 **********
Registered Address: Redmond, Washington

Key Metrics

Founded Year

2014

Location

Redmond, United States

Stage

Unfunded

Ranked

1100^th among 3337 active competitors

Employee Count

145 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3069 more

View Systimmune's full profile

Systimmune is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Systimmune, Inc. CIN: 465743763 , United States, Active	Dec 26, 999	-	89 (As on Dec 31, 2024)	-

Systimmune has not raised any funding rounds yet.

Systimmune's employee count trend

Systimmune has 145 employees as of Jul 26. Here is Systimmune's employee count trend over the years:

Uncover Systimmune's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Systimmune include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Systimmune, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1100th	Systimmune 2014, Redmond (United States), Unfunded	Biopharmaceutical company developing innovative antibody-based therapies for cancer treatment	-	-	40/100